{"id":"W1533769407","doi":"10.1038/cddis.2015.187","title":"FV-162 is a novel, orally bioavailable, irreversible proteasome inhibitor with improved pharmacokinetics displaying preclinical efficacy with continuous daily dosing","year":2015,"lang":"en","type":"article","venue":"Cell Death and Disease","topic":"Ubiquitin and proteasome pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research; University of Toronto; Princess Margaret Cancer Centre","funders":"Leukemia and Lymphoma Society","keywords":"Pharmacology; Pharmacokinetics; Proteasome; Proteasome inhibitor; Dosing; Multiple myeloma; Pharmacodynamics; Tolerability; Bioavailability; In vivo; Prodrug; Bortezomib; Medicine; Chemistry; Biology; Immunology; Adverse effect; Biochemistry","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001244225,0.0002705047,0.0002152758,0.0001443423,0.00007938354,0.0001890616,0.0001542785,0.0001945692,0.0008742144],"category_scores_gemma":[0.00006908282,0.00008794216,0.0001146838,0.0001128694,0.0001157177,0.0002126599,0.0001030413,0.0003985302,0.000210228],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002162086,"about_ca_system_score_gemma":0.0001669491,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003592577,"about_ca_topic_score_gemma":0.0008026758,"domain_scores_codex":[0.9999424,0.000006924716,0.000004087469,0.00001694102,0.00001968886,0.000009984056],"domain_scores_gemma":[0.9999658,0.000004632387,0.00001407922,0.000003259807,0.00000462873,0.000007634194],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0001483705,0.0000802656,0.0002005338,0.00005818451,0.000006055273,0.00007989498,0.000008256916,0.0003618015,0.9878208,0.0001279284,0.0001060096,0.01100199],"study_design_scores_gemma":[0.000137777,0.004385225,0.004244089,0.000008087199,0.00003692154,0.001077872,0.000009595355,0.001756836,0.9810504,0.00007454694,0.007204881,0.00001370888],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9750994,0.006473296,0.01183943,0.0001403221,0.00003346933,0.00008648528,0.0004613721,0.0001923714,0.005673672],"genre_scores_gemma":[0.9888859,0.001703313,0.005446618,0.00006009896,0.00001374044,0.00002620344,0.0004602405,0.00001567981,0.003388273],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0008742144,"threshold_uncertainty_score":0.002924562,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02637827595721043,"score_gpt":0.265230519640434,"score_spread":0.2388522436832236,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}